Furthermore, a pilot study (n=15) indicated that bevacizumab significantly decreases CSF VEGF levels over time, resulting in clinical, imaging and CSF responses, or stable disease in 54–73% of leptomeningeal metastases patients with breast cancer, lung cancer, or melanoma (10,23). The gene discussed is VEGFA; the disease is breast cancer.